Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective
oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR) …

Highlights•Understanding mechanisms of resistance in oncogene-driven lung cancer is
crucial.•MET amplification is a recurrent driver of resistance, across molecularly defined …

Purpose: The RET proto-oncogene encodes a receptor tyrosine kinase that is activated by
gene fusion in 1%–2% of non–small cell lung cancers (NSCLC) and rarely in other cancer …

Objective To compare the efficacy and safety of first line treatments for patients with
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

MET exon 14 skipping mutation (MET∆ ex14) is present about 3% of non-small cell lung
cancers (NSCLCs). NSCLC patients with MET∆ ex14 are characterized by an average age …

In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …

Simple Summary Lung cancer is the leading cause of mortality in cancer patients, causing
an estimated 1.8 million deaths in the year 2020. However, the available therapeutic options …

Targeting the MET pathway in advanced NSCLC has been of particular interest due to its
role as both a primary oncogenic driver and secondary oncogenic driver of acquired …